OncRef

Clinical Trial: NCT02210117

Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery

Status:

ACTIVE NOT RECRUITING

Phase:

Early Phase 1

Lead Sponsor:M.D. Anderson Cancer Center
Information Provided By:M.D. Anderson Cancer Center
Last Update Posted:2026-06-01

Study Overview

Brief Summary

This randomized pilot early phase I trial studies the side effects and how well nivolumab alone works compared to nivolumab with bevacizumab or ipilimumab before surgery in treating patients with kidney cancer, also referred to as renal cell cancer, that has spread to another place in body and can be removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, bevacizumab, and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Official Title

A Pilot Randomized Tissue-Based Study Evaluating Anti-PD1 Antibody or Anti-PD1 + Bevacizumab or Anti-PD1 + Anti-CTLA-4 in Patients With Metastatic Renal Cell Carcinoma Who Are Eligible for Cytoreductive Nephrectomy, Metastasectomy or Post-Treatment Biopsy

Conditions

Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage IV Renal Cell Cancer AJCC v7

Intervention / Treatment

  • Biological: Bevacizumab
  • Procedure: Biopsy
  • Biological: Ipilimumab
  • Other: Laboratory Biomarker Analysis
  • Procedure: Metastasectomy
  • Biological: Nivolumab
  • Procedure: Therapeutic Conventional Surgery

Other Study ID Numbers

  • 2013-0715
  • NCI-2014-01857
  • 2013-0715

Start Date (Actual)

2014-11-25

Primary Completion Date (Estimated)

2026-12-31

Study Completion Date (Estimated)

2026-12-31

Enrollment (Actual)

104

Study Type

Interventional

Phase

Early Phase 1